Home >> Research Area >>NF-κB>>IκB/IKK>> Choline Fenofibrate

Choline Fenofibrate

Choline salt of fenofibric acid CAS# 856676-23-8

Choline Fenofibrate

Catalog No. BCC1478----Order now to get a substantial discount!

Product Name & Size Price Stock
Choline Fenofibrate: 5mg $58 In Stock
Choline Fenofibrate: 10mg Please Inquire In Stock
Choline Fenofibrate: 20mg Please Inquire Please Inquire
Choline Fenofibrate: 50mg Please Inquire Please Inquire
Choline Fenofibrate: 100mg Please Inquire Please Inquire
Choline Fenofibrate: 200mg Please Inquire Please Inquire
Choline Fenofibrate: 500mg Please Inquire Please Inquire
Choline Fenofibrate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Choline Fenofibrate

Number of papers citing our products

Chemical structure

Choline Fenofibrate

3D structure

Chemical Properties of Choline Fenofibrate

Cas No. 856676-23-8 SDF Download SDF
PubChem ID 11350701 Appearance Powder
Formula C22H28ClNO5 M.Wt 421.91
Type of Compound N/A Storage Desiccate at -20°C
Synonyms ABT-335
Solubility Ethanol : 33.33 mg/mL (79.00 mM; Need ultrasonic)
DMSO : 20 mg/mL (47.40 mM; Need ultrasonic)
Chemical Name 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate;2-hydroxyethyl(trimethyl)azanium
SMILES CC(C)(C(=O)[O-])OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl.C[N+](C)(C)CCO
Standard InChIKey JWAZHODZSADEHB-UHFFFAOYSA-M
Standard InChI InChI=1S/C17H15ClO4.C5H14NO/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11;1-6(2,3)4-5-7/h3-10H,1-2H3,(H,20,21);7H,4-5H2,1-3H3/q;+1/p-1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Choline Fenofibrate

DescriptionCholine Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. IC50 value: Target: Several clinical trials have been developed with Choline Fenofibrate on Reverse Cholesterol Transport, Macular Edema and Hypertriglyceridemia.

References:
[1]. Jones PH, Bays HE, Davidson MH et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28(10):625-34. [2]. Mohiuddin SM, Pepine CJ, Kelly MT et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203. [3]. Zhu T, Awni WM, Hosmane B et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009 Jan;49(1):63-71. [4]. Goldberg AC, Bays HE, Ballantyne CM et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15;103(4):515-22. [5]. Campbell J, Mohiuddin SM. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Drugs Today (Barc). 2010 Oct;46(10):757-64.

Choline Fenofibrate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Choline Fenofibrate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Choline Fenofibrate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.3702 mL 11.8509 mL 23.7017 mL 47.4035 mL 59.2543 mL
5 mM 0.474 mL 2.3702 mL 4.7403 mL 9.4807 mL 11.8509 mL
10 mM 0.237 mL 1.1851 mL 2.3702 mL 4.7403 mL 5.9254 mL
50 mM 0.0474 mL 0.237 mL 0.474 mL 0.9481 mL 1.1851 mL
100 mM 0.0237 mL 0.1185 mL 0.237 mL 0.474 mL 0.5925 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Choline Fenofibrate

Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. Several clinical trials have been developed with Choline Fenofibrate on Reverse Cholesterol Transport, Macular Edema and Hypertriglyceridemia.

Featured Products
New Products
 

References on Choline Fenofibrate

Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry.[Pubmed:27594083]

Biomed Chromatogr. 2017 Apr;31(4).

Choline Fenofibrate is the choline salt of fenofibric acid, which releases free fenofibric acid in the gastrointestinal tract. To estimate the absolute oral bioavailability of fenofibric acid and Choline Fenofibrate, a novel and sensitive UPLC-MS/MS method with liquid-liquid extraction procedure was developed for the determination of fenofibric acid in rat plasma. The separation was achieved on a Phenomenex Kinetex C18 column (50 x 2.1 mm, 2.6 mum) containing 2 mm ammonium acetate-methanol with a gradient elution program. Validations of this method including specificity, sensitivity (limit of quantification, 5 ng/mL), linearity (0.005-10 mug/mL), accuracy (within +/-4.3%), precision (intra- and inter-day coefficient of variation <11.3%), recovery (94.9-105.2% for fenofibric acid), matrix effect, stability and dilution, were all within acceptable limits. This method successfully supported the determination of fenofibric acid and Choline Fenofibrate. The absolute oral bioavailability was 93.4% for Choline Fenofibrate and 40.0% for fenofibric acid. These results suggested that Choline Fenofibrate and fenofibric acid had a better in vivo pharmacokinetic behavior than that of fenofibrate. The two new orally administrated pharmaceuticals, fenofibric acid and Choline Fenofibrate, can be developed as alternatives to fenofibrate.

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population.[Pubmed:26904471]

Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):67-71.

INTRODUCTION: Choline Fenofibrate is a newly developed choline salt of fenofibric acid, which is more hydrophilic than fenofibrate. This study was initiated to evaluate the safety and efficacy of Choline Fenofibrate in comparison to micronized fenofibrate among Indian patients of mixed dyslipidemia. METHODS: A multicenter, open-label, randomized, active controlled, comparative, parallel group study was conducted at around 10 centers spread all across the country. Mixed dyslipidemia patients (serum triglycerides [TG] levels between 150 and 500 mg/dl), aged 18-70 years and taking stable statin dose for 8 weeks were randomized to Choline Fenofibrate 135 mg delayed release tablets and micronized fenofibrate 160 mg tablets once daily for 12 weeks. The primary endpoint of the study was percentage change in serum TG level at the end of 12 weeks. RESULTS: A total of 226 patients were enrolled in this study, of which 116 patients were administered Choline Fenofibrate and 110 patients were administered micronized fenofibrate. At the end of 12 weeks, there was a significant reduction in TG level (34.24% in Choline Fenofibrate group and 38.13% reduction in micronized fenofibrate group). However, the difference between group was not statistically different (P = 0.471). Similarly, there was a significant increase in high-density lipoprotein cholesterol at the end of 12 weeks (10% increase in Choline Fenofibrate group and 9% increase in micronized fenofibrate group); but the difference between the group was not statistically significant (P = 0.598). Both the treatment was safe and well tolerated. CONCLUSION: Choline Fenofibrate delayed release 135 mg is as safe and effective as 160 mg of micronized fenofibrate in Indian patients with mixed dyslipidemia.

Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs.[Pubmed:26024820]

Int J Pharm. 2015 Jul 25;490(1-2):273-80.

The objective of this study was to develop a novel fenofibric acid-loaded controlled release pellet showing enhanced, or equivalent to, bioavailability compared with two commercially available products containing fenofibrate or Choline Fenofibrate. The effect of solubilizing agents on drug solubility and the impact of fillers on core properties were investigated. Among them, magnesium carbonate most improved drug solubility, and kappa-carrageenan provided the best spherical cores. The fenofibric acid-loaded pellet was prepared with magnesium carbonate and kappa-carrageenan employing the extrusion/spheronizing technique followed by coating with ethylcellulose. Furthermore, dissolution and pharmacokinetic study in beagle dogs were performed compared to the fenofibrate-loaded commercial tablet (FCT) and Choline Fenofibrate-loaded commercial mini-tablet (CFCM). This fenofibric acid-loaded pellet showed controlled release of the drug in phosphate buffer (pH 6.8) and 0.025 M sodium laurylsulfate within 4h. Furthermore, this pellet and CFCM exhibited similar dissolution profiles. Plasma concentrations greater than 1,000 ng/ml were maintained from 30 min to 8h, suggesting a sustained release pattern. Also, the fenofibric acid-loaded pellet gave significantly higher AUC and Cmax values than FCT, indicating that it improved the bioavailability of fenofibrate due to enhanced solubility and sustained release. In addition, this pellet and CFCM were not significantly different in terms of pharmacokinetic parameters including AUC, Cmax and Tmax. Thus, this pellet was bioequivalent to CFCM in beagle dogs. In conclusion, this fenofibric acid-loaded controlled release pellet would be a potential alternative to the Choline Fenofibrate-loaded commercial product.

Description

Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia.

Keywords:

Choline Fenofibrate,856676-23-8,ABT-335,Natural Products,IκB/IKK, buy Choline Fenofibrate , Choline Fenofibrate supplier , purchase Choline Fenofibrate , Choline Fenofibrate cost , Choline Fenofibrate manufacturer , order Choline Fenofibrate , high purity Choline Fenofibrate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: